Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

in a retrospective review of 133 patients treated with polaBR for relapsed / refractory DLBCL showed a 57% ORR and a 31% CR rate, median PFS was 4.8 months and median OS was 8.2 months.

Read the full article here

Related Articles